Augment Biologics
Augment Biologics Inc. is transforming biologic drug development with its AI-guided glycoprotein-drug design platform, GlycoTemplating. This platform enables precise site-specific glycan engineering by writing glycans directly into the primary sequence of biologics, improving efficacy, safety, durability, and manufacturing. Unlike traditional methods that face limitations like high costs and unpredictability, GlycoTemplating offers an expression platform agnostic approach to glycoengineering. The company's technology is founded on discoveries in glycan biosynthesis and uses a multi-view neural network to predict, modify, and stabilize glycosylation on any biologic. Augment Biologics is initially focusing on antibody, protein, and peptide engineering, with future applications in RNA therapeutics, delivery vehicles, and vaccine development.
Augment Biologics
Augment Biologics Inc. is transforming biologic drug development with its AI-guided glycoprotein-drug design platform, GlycoTemplating. This platform enables precise site-specific glycan engineering by writing glycans directly into the primary sequence of biologics, improving efficacy, safety, durability, and manufacturing. Unlike traditional methods that face limitations like high costs and unpredictability, GlycoTemplating offers an expression platform agnostic approach to glycoengineering. The company's technology is founded on discoveries in glycan biosynthesis and uses a multi-view neural network to predict, modify, and stabilize glycosylation on any biologic. Augment Biologics is initially focusing on antibody, protein, and peptide engineering, with future applications in RNA therapeutics, delivery vehicles, and vaccine development.